How to identify great biotech companies. Also my track record below. 1. Undervalued (low market cap vs assets and market potential). 2. Solid management (biotech experience, CEO track record and reputation, not too many turnovers). 3. Great pipeline versus what’s currently.

$AQST $IOVA - Have a nice long Labor Day weekend 🐉 family. I can tell you with my utmost confidence that these two tickers will be two of the most rewarding investments you’ve ever made. Will it be easy? No. Will they always be green every day? No. Will they both end up in the.

Join millions who have switched to Grok.

$IOVA - The EU in asking for additional data on Amtagvi while many stage 4 metastatic melanoma patients in the EU are dying and are out of options. Meanwhile while Amtagvi is saving lives every day in the US and soon Canada. The EU should have looked at the 5 year real world.

$IOVA- Upcoming conferences .

$IOVA $AQST - Iovance should double the salary and bring Sherry Korczynski over. Oh hell… here comes the venom 😆.

$IOVA - The need for personalized cell therapy like TIL therapy is needed more than ever. Gastrointestinal (GI) cancers (such as stomach, colorectal, pancreatic, liver, and esophageal cancers) are on the rise and in younger adults. Next generation TIL like IOV 4001 (PD-1.

$IOVA $AQST - What you can always count on are roaches coming from the basement when we have red days. They spew conspiracies and FUD instead of sharing DD or words of encouragement to the community. They bash management and the people who share information to help the community.

$IOVA - Let the shorts pile in as their eventual demise awaits

$AQST - This is a must read regardless if you’re an investor or not. My goal here with my posts is not just about investing but educating about how to deal with severe allergic reactions and anaphylaxis. More specifically about saving lives. Many people INCLUDING PHYSICIANS.

$IOVA - Stage 4 melanoma has been a death sentence to ALL whom received this news. unTIL Amtagvi came along. Now oncologists and patients don’t just hope for improvement but a possibility of a CURE. This is just the beginning. Why is Iovance also looking at treating other solid.

$IOVA - Remember on September 18, 2025 Iovance Biotherapeutics will be receiving an award in Denver, CO for pioneering TIL therapy. Their pioneering work is saving lives with every infusion of Amtagvi. Like I said, soon $IOVA will be a household name in treating solid tumors that

$IOVA - Worth repeating!.

$IOVA - In ALL of my scientific background and education and 18 years of pharmaceutical experience, I can tell you right now that Amtagvi WILL BE APPROVED with a 99.9% level of confidence for second line NSCLC. There is not much else after chemo and ICI (Immune Checkpoint.

$IOVA - I had a privilege of talking to a fellow $IOVA investor and oncologist yesterday. You think I am bullish? Only if you knew the number of shares he owns. My goodness! This person attends oncology conferences. Iovance is making serious noises in precision cell and gene.

$IOVA - Ideally, the first catalyst dropped should be the marketing approval of Amtagvi for Switzerland. After that, IOV-4001 data for melanoma (I am most excited about this one actually). Then phase 2 endometrial cancer and last and the shorts killing catalyst- NSCLC updated.

$IOVA - TIL therapy is the most personalized cancer treatment available today. CAR-T can’t even match the specificity of Amtagvi. This is why CAR-T is still struggling with solid tumors that make up 90% of all cancers! It can’t get more personalized than removing the very T-cells.

$AQST - Up coming conferences. Webcast available at the Cantor and HC Wainwright.

$IOVA - Seeing people selling at current prices is nothing short of tragic. It’s the transfer of wealth from the impatient to the smart investors. Only if you knew what’s coming…🤑.

$IOVA - By far the biggest catalyst for the second half of 2025 is the NSCLC data. Even though each of the other three catalysts are also massive in their own way. So what is the clinical trial that we are talking about?. What is IOV-LUN-202?. It is a “Phase 2, open-label,.

$IOVA - Why shorts can’t sleep well at night before the next earnings: #3 is the biggest one. Referrals are picking up to get patients to Amtagvi treatment sooner. This will impact margins tremendously. Healthier patients yield better TIL quality leads to fewer drop offs. 1.